Delayed
Nasdaq
10:43:30 2024-04-29 EDT
5-day change
1st Jan Change
6.067
USD
+4.06%
+22.81%
-34.82%
SIGNAL Huntington’s Disease Trial (VX15-2503-N-131): Cohort B Topline Results
September 22, 2020 at 11:00 am
Vaccinex, Inc. SIGNAL (VX15-2503-N-131) Cohort B Topline Results
September 22, 2020 @8:30 AM
Forward Looking Statement
To the extent that statements contained in this presentation are not descriptions of historical facts
regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements
reflecting management's current beliefs and expectations. Such statements include, but are not
limited to, statements about our plans, expectations and objectives with respect to the results and
timing of our Phase 2 SIGNAL trial of pepinemab (VX15/2503) in Huntington's disease and other
clinical trials, the use and potential benefits of pepinemab in Huntington's disease and other
indications, and other statements identified by words such as "may," "will," "appears," "expect,"
"anticipate," "estimate," "intend," "hypothesis," "potential," "advance," and similar expressions or
their negatives (as well as other words and expressions referencing future events, conditions, or
circumstances). Forward-looking statements involve substantial risks and uncertainties that could
cause the outcome of our research and pre-clinical development programs, clinical development
programs, future results, performance, or achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and uncertainties include, among others,
uncertainties inherent in the execution, cost and completion of preclinical and clinical trials,
uncertainties related to regulatory approval, risks related to our dependence on our lead product
candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our
development plans or the commercial potential of our product candidates. Except as required by law,
we assume no obligation to update these forward-looking statements. For a further discussion of
these and other factors that could cause future results to differ materially from any forward-looking
statement, see the section titled "Risk Factors" in our periodic reports filed with the Securities and
Exchange Commission ("SEC") and the other risks and uncertainties described in our Form 10-K dated
2
March 9, 2020 and subsequent filings with the SEC.
One Touch Stockings (OTS) - Cohort B1 Co-Primary 1a: Cognitive Assessment
One-
Success
sided p-
Favors
[Critical
value
PEPI
value]
0.028
Yes
No
[0.025]
[0.0125]
Difference (PEPI - PBO)
Change from Baseline at Month 17 (95% CI) = -1.98(-4.00, 0.05)
3
OTS Assessment of Executive Function - Planning and Memory
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original document
Permalink
Disclaimer
Vaccinex Inc. published this content on 22 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2020 14:59:08 UTC
Vaccinex, Inc. announced that it has received $1.75 million in funding
04-11
CI
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
04-02
CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding
03-28
CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C
03-27
CI
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C
03-26
CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding
03-26
CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024
03-04
CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024
03-04
CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
02-21
MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform
02-21
MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
02-21
CI
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding
02-06
CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-13
CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting
23-10-31
CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
23-10-26
CI
Top Premarket Gainers
23-10-06
MT
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing
23-10-05
MT
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing
23-10-05
MT
Top Midday Decliners
23-09-29
MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected
23-09-29
MT
Top Premarket Decliners
23-09-29
MT
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million
23-09-29
MT
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs
23-09-28
CI
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study
23-09-27
CI
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
23-09-26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1